Table 2.

Descriptive results of both overall yearly expenditures and DDDs in the drug category and Administration and compared drug for each observed year (2015–2019).

	Expenditure (10 thousand yuan)					DDDs (10 thousand)
Year	2015	2016	2017	2018	2019	2015	2016	2017	2018	2019
18 drug	281202.12	330210.79	403474.66	626757.92	862207.87	532.65	604.85	800.23	1485.71	2145.51
Drug categories
15 western medicines	262553.04	309595.64	386554.78	614855.50	845369.60	186.67	224.49	409.95	1226.21	1887.59
L01: Antineoplastic agents	258270.89	301784.74	373431.17	550871.97	737614.67	174.02	202.93	356.39	939.62	1395.33
Monoclonal antibodies	183955.59	216082.01	263050.43	385996.27	551246.36	115.12	131.44	240.52	689.45	1092.12
Protein kinase inhibitors	33718.90	39916.18	48776.27	82523.25	105834.90	38.82	47.31	76.73	178.59	227.93
Protease inhibitor	20945.14	21185.99	32900.94	44356.24	34839.81	7.06	7.21	15.88	32.19	26.87
Other antineoplastic agents	19651.27	24600.57	28703.54	37996.21	45693.60	13.02	16.96	23.27	39.40	48.41
L02: Endocrine therapy	1580.58	4117.37	9217.09	47362.83	82257.55	8.94	16.46	46.53	248.43	433.84
L04: Immunosuppressants	2701.57	3693.54	3906.52	16620.71	25497.38	3.71	5.10	7.03	38.17	58.42
3 traditional Chinese medicines	18649.08	20615.15	16919.88	11902.42	16838.27	345.97	380.37	390.28	259.50	257.92
Administration
Inject	230288.13	269786.99	331435.02	483803.07	659917.06	151.83	180.93	324.80	962.58	1520.72
Table/capsule	50913.99	60423.80	72039.64	142954.85	202290.81	380.81	423.92	475.42	523.14	624.80
Compared group1
Bevacizumab	32481.69	37860.51	53310.42	101442.09	161566.36	25.08	29.18	62.65	205.14	335.22
Cetuximab	17470.25	17643.99	21569.58	21198.25	50363.49	3.54	3.55	4.69	6.43	33.51
Compared group2
Erlotinib	15707.89	12347.35	9990.14	9299.17	9473.11	26.06	22.42	27.96	49.26	52.21
Crizotinib	1715.2	3251.91	4135.88	4245.42	39502.05	0.97	1.83	2.33	5.48	76.37